New drug LY3971297 tested for obesity and hypertension safety

NCT ID NCT06148272

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called LY3971297 in healthy volunteers, people with obesity and high blood pressure, and those with reduced kidney function. The main goal is to check for side effects and measure how the drug moves through the body. The study involves up to 225 participants and lasts up to 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3971297
What this could lead to: If successful, this could lead to a new treatment option for obesity and high blood pressure.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not effectiveness. It is small and may not lead to a working treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HYPERTENSION OBESITY

Contacts and locations

Locations

CenExel ACT

Anaheim, California, 92801, United States
Clinical Pharmacology of Miami

Miami, Florida, 33172, United States
Clinical Research Hospital Tokyo

Shinjuku-ku, 160-0004, Japan
Hakata Clinic

Fukuoka, 812-0025, Japan
ICON Early Phase Services

San Antonio, Texas, 78209, United States
Lilly Centre for Clinical Pharmacology

Singapore, 138623, Singapore
P-One Clinic

Hachiōji, 192-0071, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.